Oncology Business Management

As rumors circulate in Washington, DC, ASCO has called for efforts to reach a consensus on drug value to ensure affordability and access for patients and spur manufacturers to work harder on bringing innovative medicines to market.

The FDA’s Oncologic Drugs Advisory Committee voted 16-0 to recommend approval to MYL-1401O, the trastuzumab (Herceptin) biosimilar manufactured by Mylan Pharmaceuticals.

The FDA’s Oncologic Drugs Advisory Committee voted 17-0 to recommend approval for ABP-215, a biosimilar for bevacizumab (Avastin) to treat a range of solid tumors.